Arcus Biosciences, Inc. Receives Consensus 'Buy' Recommendation from Ten Research Institutions, Target Price Adjustments

Summary

Arcus Biosciences, Inc. (NYSE: RCUS) received a unanimous ‘buy’ recommendation from ten research institutions. One analyst rated it as ‘hold,’ eight as ‘buy,’ and one as ‘strong buy,’ with an average target price of $30.25. Recently, Bank of America lowered its target price to $17.00, and Morgan Stanley reduced it to $25.00. Board member Yasunori Kaneko and CEO Terry J. Rosen made insider purchases. Institutional investors hold 92.89% of the stock. The opening price is $7.01, with a 52-week price range of $6.50 to $18.98. Market Beat

Impact Analysis

The event is classified at the company level, as it focuses on analyst recommendations and target price adjustments specific to Arcus Biosciences. The ‘buy’ ratings suggest positive sentiment and potential upside in stock valuation. Despite recent target price reductions by major institutions, insider purchases indicate confidence in the company’s prospects. First-order effects include potential increased investor interest and trading volume in Arcus Biosciences stocks. Second-order effects may involve influence on sector sentiment, where biotech stocks could gain traction. Investment opportunities lie in considering Arcus Biosciences’ stock potentially being undervalued given its opening price of $7.01 against an average target of $30.25, highlighting potential for upside. Market Beat